P
CRSP icon

&Partners’s CRISPR Therapeutics CRSP Stock Holding History

&Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Buy
5,481
+531
+11% +$28K ﹤0.01% 2135
2026
Q1 		$240K Buy
+4,950
New +$261K ﹤0.01% 2137
2025
Q4 		– Sell
-3,484
Closed -$226K – 2297
2025
Q3 		$226K Buy
+3,484
New +$200K ﹤0.01% 1906

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

&Partners's CRSP Position: Q2 2026 in Review

&Partners increased its CRISPR Therapeutics (CRSP) stake by 11% in Q2 2026, buying an estimated $28K and bringing the position to 5,481 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #2135.

&Partners first reported a position in CRSP in Q3 2025 and has held it in 3 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • &Partners held 5,481 shares of CRISPR Therapeutics worth $299K as of Q2 2026.
  • &Partners bought 531 CRISPR Therapeutics shares in Q2 2026, an estimated $28K.
  • CRISPR Therapeutics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2135 holding.
  • &Partners first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.